Cellino
AI-driven biomanufacturing for personalized stem cell therapies
Cellino is a visionary but pre-commercial play. If you're planning future R&D or hospital infrastructure for personalized cell therapy, it's worth watching. For immediate clinical needs, look elsewhere.
Verified 10d ago · liveness 60/100 · cite: rightaichoice.com/tools/cellino
- R&D scalability for autologous cell therapies
- Future hospital-based localized cell manufacturing
- Developers of personalized therapies for degenerative diseases
- Patients seeking immediate treatments (still in development)
- Off-the-shelf allogeneic therapies (focus is autologous)
- Low-budget research labs (likely high-cost platform)
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Cellino if you need a commercially available platform today or if you're a low-budget lab seeking immediate solutions—it's a pre-commercial, likely high-cost system still in development.
As a pre-commercial platform, the Nebula system will likely have a significant upfront capital cost for labs or hospitals acquiring it.
Cellino has no published pricing, typical for pre-commercial biotech platforms. Expect enterprise-level costs rather than research-lab-friendly pricing. Compared to manual bioprocessing methods, it aims to reduce long-term labor and variability costs, but the initial investment is unknown.
In short
Cellino — AI-driven biomanufacturing for personalized stem cell therapies. Best for R&D scalability for autologous cell therapies, Future hospital-based localized cell manufacturing, Developers of personalized therapies for degenerative diseases. Contact Sales pricing.
Viability Score
How well maintained and how widely used is Cellino? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- AI-driven optical bioprocess
- Laser-generated bubbles for cell removal
- Deep learning for reproducible biomanufacturing
- Cellinoverse digital environment for in silico simulation
- Nebula modular cassette-based platform
- Closed-loop image-guided bioprocess
- Autonomous processing minimizing human variability
- Scalable production of biologically younger stem cells
- Personalized one-time treatments from patient's own cells
- Eliminates need for immunosuppression
- Modular systems for hospital localization
- Demonstrated tissue manufacturing across diverse patient backgrounds
About Cellino
Cellino is building the Nebula platform to automate the production of personalized stem cell therapies using deep learning, laser optics, and closed-loop image-guided bioprocesses. Targeting chronic degenerative diseases—Parkinson's, diabetes, macular degeneration, and more—the platform compresses traditional biomanufacturing into modular cassette-based systems deployable in hospitals or large-scale foundries. The company is pre-commercial, with recent milestones proving tissue manufacturing works across diverse patient backgrounds, and recognition on Fast Company's Most Innovative Companies of 2026 list. For researchers and future clinicians, Cellino represents a path to scalable, personalized regenerative medicine, reducing human variability and eliminating the need for immunosuppression by using patient's own cells. Unlike manual methods or allogeneic approaches, Cellino's AI-driven optical processes aim for reproducibility and patient-specificity, positioning it as a forward-looking player in the biomanufacturing space.
Behind the Verdict
Cellino is tackling one of the hardest problems in medicine: manufacturing personalized cell therapies at scale. Its Nebula platform combines deep learning, laser optics, and closed-loop image-guided bioprocesses to automate the production of a patient's own stem cells, targeting diseases like Parkinson's, diabetes, and macular degeneration. The company is pre-commercial, but its recent milestone—showing tissue manufacturing works across any patient background—suggests real progress. The technology is designed to be deployed in hospitals or distributed foundries, which could dramatically expand access to autologous therapies that currently require centralized, manual production. Strengths: The laser-based cell management and AI-driven optical bioprocess aim to eliminate human variability, which is a major bottleneck in manual cell culture. The Cellinoverse digital twin allows in silico simulation, potentially speeding up process development. The modular cassette design is a thoughtful approach to scalability and localization. Weaknesses: As a pre-commercial platform, there's no validated production line or regulatory approval yet. The cost of the platform is likely high, and the technology is unproven in clinical settings. It's not suitable for researchers low on budget or for patients seeking immediate treatments. Where it fits: R&D teams planning future autologous cell therapy pipelines, hospital systems investing in regenerative medicine infrastructure, and biotech companies looking to partner on scalable manufacturing. Where it doesn't: Patients with current unmet needs, low-budget labs, and companies focused on off-the-shelf allogeneic therapies.
Researching Cellino? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Cellino actually fits — and what changes day-one when you adopt it.
Planning to automate iPSC manufacturing for a new personalized cell therapy project.
Outcome: You could evaluate Cellino's platform for pilot studies, using the Cellinoverse digital twin to simulate bioprocesses before physical trials, potentially accelerating development.
Considering localizing cell therapy production to expand patient access.
Outcome: You might assess Nebula's modular cassette systems for on-site manufacturing, enabling one-time autologous treatments without immunosuppression, but only after clinical validation.
Looking for scalable manufacturing partners for autologous cell therapies.
Outcome: You could engage Cellino as a potential partner for future clinical trials, leveraging their AI-driven optical bioprocess to achieve reproducible, patient-specific batches.
Use Cases
- Automate iPSC manufacturing for personalized cell replacement therapies targeting degenerative diseases.
- Produce consistent, high-quality stem cell batches for research or clinical trials with AI-guided optical control.
- Scale up cell therapy production from lab to commercial volumes using modular, cassette-based Nebula systems.
- Eliminate manual variability in cell culture by deploying closed-loop image-guided bioprocesses.
- Establish localized cell therapy manufacturing hubs in hospitals to increase patient access.
- Simulate and optimize biomanufacturing workflows in silico using the Cellinoverse digital twin.
Models Under the Hood
as of 2026-08-31
Limitations
- Current details are limited to the company's mission and technology overview.
- No pricing, specific product specifications, or release timelines are provided, suggesting the platform may be in development.
- The system targets advanced biomanufacturing for personalized stem cell therapies, requiring specialized knowledge in biology, engineering, and AI.
- No explicit API or developer platform details are mentioned.
as of 2026-08-28
Verification history
We have re-verified Cellino 16 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 16 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Cellino's pricing actually pencils out — and where peers do it cheaper.
Cellino has no published pricing, typical for pre-commercial biotech platforms. Expect enterprise-level costs rather than research-lab-friendly pricing. Compared to manual bioprocessing methods, it aims to reduce long-term labor and variability costs, but the initial investment is unknown.
Setup time & first value
How long it actually takes to get something useful out of Cellino — broken out by persona, not the marketing-page minute.
For research collaboration: No setup possible today—platform is pre-commercial; expect years before deployment. For hospital planning: Not yet available; monitor progress for future implementation timelines.
Switching to or from Cellino
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual cell culture: Adopting Nebula would replace manual steps with automated optical bioprocesses, but is currently in development—no migration path exists yet.
- ↗To other bioprocessing platforms: Not applicable as Cellino is pre-commercial; no established migration path.
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with Cellino
Common stack mates teams adopt alongside Cellino, with the specific reason each pairing earns its keep.
Recursion Pharmaceuticals
AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies
Tempus
AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care.
Insitro
Causal AI for human health, turning 20+ petabytes of cellular data into targeted therapeutics.
Alternatives to Cellino
View allRecursion Pharmaceuticals
AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies
Frequently Asked Questions
Categories
Best-of guides
Used Cellino? Help shape our editorial sentiment research.